References
- Greenspan E M, Erlich R. Levamisole and the new era of therapy. Cancer Invest 1991; 9: 111–124
- Cancer News Lett 1989; 15: 1–5, and 48:7; 16:5–8, 1990
- Haller D G, Catallano P J, Macdonald J S. Fluorouracil, leuco-vorin and levamisole adjuvant therapy for colon cancer: tive-year final report of INT-0089. Proc ASCO 1998; 17: 982
- Mathe G, Amie N L, Schwartzenberg L. Active immunother-apy for acute lymphohlastic leukemia. Lancet 1969; 1: 697
- Greenspan E M. Is BCG an “Orphan” drug suffering from che-motherapist's overkill. Cancer Invest 1986; 4: 81–92
- Morton D L, Holmes E C, Elker F R. Adjuvant immunotherapy of malignant melanoma. Results of a randomized trials in patients with lymph node metastases. Immunology of Human Cancer, WD Terry, SA Rosenberg. Elsevier, North Holland 1982; 245–249
- Hoover H C, Brandhorsl J S, Peters I C. Adjuvant active specific immunotherapy for human colorectal cancer: 61/2-year median follow-up of a phase III respectively randomized trial. J Clin Oncol 1993; 11: 390–399
- Rosenberg S SA, Lotze MT., Murel L M. Observations on the syntemic administration of autologous lymphokine activated cells and recombinant IL 2 in patients with metastatic cancer. N Engl J Med 1985; 313: 1485–1492
- Megrier S, Escudier B, Lasset C. Recombinant human IL-2, recombinant human interferon alfa-2 or both in metastatic renal cell cancer. N Engl J Med 1998; 338: 3272–3278
- Kammula U S, White DE., Rosenberg S A. Trends in the safety of administration of high dose interleukin-2 in patients with metastatic cancer. Proc ASCO 1998; 17: 1684
- Slamon D, Leyland-Jones Shak B. S. Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc ASCO 1998; 17: 377
- Burris H A, Moore M, Rothenberg M. Improvement in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413
- McDermott D F, Mier J W, Lawrence D P. A phase II pilot trial of concurrent biochemotherapy with cisplatin. vinhlastine. dacarbazine, interleukiii-2 and interferon alpha-2B (IFN) in patients with metastatic melanoma. Proc ASCO 1956; 17: 1998
- Kirkwood J M, Strawderman M H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group EST 1684. J Clin Oncol 1996; 14: 7–17
- Golomb H M, Jacobs Fefer A. A. Alpha-2 interferon therapy of hairy- cell leukemia: a multicenter study of 64 patients. J Clin Oncol 1986; 4: 900–905
- Andersen J W, Smalley R V. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year followup. N Eng J Med 1993; 329: 1821–1822
- Maloney D G, Grillo-Lopez A J, White C A. IDEC-C288 (RI-TUXIMAB) antiLCD 20 monoclonal antibody therapy in patients with low grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195